WNT8A

Summary

WNT8A (Wnt family member 8A, HGNC:12788) is a protein-coding gene on chromosome 5q31.2, encoding Protein Wnt-8a (Q9H1J5). Ligand for members of the frizzled family of seven transmembrane receptors.

The WNT gene family consists of structurally related genes which encode secreted signaling proteins. These proteins have been implicated in oncogenesis and in several developmental processes, including regulation of cell fate and patterning during embryogenesis. This gene is a member of the WNT gene family, and may be implicated in development of early embryos as well as germ cell tumors. Multiple alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 7478 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 56 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_001300939

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12788
Approved symbol	WNT8A
Name	Wnt family member 8A
Location	5q31.2
Locus type	gene with protein product
Status	Approved
Aliases	WNT8D
Ensembl gene	ENSG00000061492
Ensembl biotype	protein_coding
OMIM	606360
Entrez	7478

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 nonsense_mediated_decay

ENST00000361560, ENST00000398754, ENST00000504809, ENST00000506684

RefSeq mRNA: 3 — MANE Select: NM_001300939 NM_001300938, NM_001300939, NM_058244

CCDS: CCDS43368, CCDS75311

Canonical transcript exons

ENST00000506684 — 5 exons

Exon	Start	End
ENSE00000764340	138087806	138087931
ENSE00000764341	138088927	138089069
ENSE00000973490	138084498	138084636
ENSE00002070199	138090528	138091541
ENSE00002073821	138084033	138084283

Expression profiles

Bgee: expression breadth broad, 33 present calls, max score 68.96.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1947 / max 31.5886, expressed in 52 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
58745	0.1236	40
58744	0.0711	28

Top tissues by expression

236 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	68.96	gold quality
pancreatic ductal cell	CL:0002079	62.29	silver quality
tibialis anterior	UBERON:0001385	62.01	silver quality
ileal mucosa	UBERON:0000331	59.18	silver quality
sperm	CL:0000019	58.13	gold quality
mucosa of paranasal sinus	UBERON:0005030	57.78	gold quality
tibia	UBERON:0000979	57.35	gold quality
epithelial cell of pancreas	CL:0000083	54.93	gold quality
superficial temporal artery	UBERON:0001614	54.76	gold quality
cardiac muscle of right atrium	UBERON:0003379	54.34	gold quality
left ventricle myocardium	UBERON:0006566	54.23	gold quality
nucleus accumbens	UBERON:0001882	54.18	gold quality
kidney epithelium	UBERON:0004819	53.93	gold quality
upper arm skin	UBERON:0004263	53.52	gold quality
deltoid	UBERON:0001476	53.47	gold quality
putamen	UBERON:0001874	51.97	gold quality
parietal pleura	UBERON:0002400	51.18	gold quality
caudate nucleus	UBERON:0001873	50.78	gold quality
visceral pleura	UBERON:0002401	50.76	gold quality
myocardium	UBERON:0002349	50.25	gold quality
medial globus pallidus	UBERON:0002477	49.65	gold quality
lateral globus pallidus	UBERON:0002476	49.42	gold quality
Brodmann (1909) area 9	UBERON:0013540	49.34	gold quality
quadriceps femoris	UBERON:0001377	49.05	gold quality
prefrontal cortex	UBERON:0000451	48.99	gold quality
globus pallidus	UBERON:0001875	48.96	gold quality
right frontal lobe	UBERON:0002810	48.88	gold quality
substantia nigra pars reticulata	UBERON:0001966	48.23	gold quality
upper leg skin	UBERON:0004262	48.18	silver quality
middle temporal gyrus	UBERON:0002771	48.01	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-9388	yes	415.96
E-ANND-3	yes	2.95

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): PRDM1

miRNA regulators (miRDB)

29 targeting WNT8A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-4527	99.66	67.43	714
HSA-MIR-6715B-5P	99.64	69.63	1420
HSA-MIR-6503-5P	99.62	66.96	597
HSA-MIR-4269	99.55	69.89	1373
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-642A-5P	99.51	65.10	1152
HSA-MIR-548AV-3P	99.43	68.50	1721
HSA-MIR-520F-5P	99.34	70.40	1632
HSA-MIR-4426	99.17	66.74	1949
HSA-MIR-361-5P	98.95	70.16	1340
HSA-MIR-181A-2-3P	98.91	67.60	1168
HSA-MIR-374A-3P	98.87	67.82	1531
HSA-MIR-7113-3P	98.75	65.71	1120
HSA-MIR-26B-3P	98.71	67.49	1102
HSA-MIR-2117	98.48	67.97	1307
HSA-MIR-6516-5P	98.42	70.19	1551
HSA-MIR-6509-3P	98.32	67.33	1343
HSA-MIR-12120	98.05	68.44	1768
HSA-MIR-4286	97.20	64.37	1587
HSA-MIR-346	97.01	66.97	662

Literature-anchored findings (GeneRIF, showing 4)

• Expression and regulation of WNT8A mRNA in human tumor cell lines (PMID:11956596)
• the WNT8A gene is involved in the susceptibility to HSCR, and plays an important role in the occurrence and development of Hirschsprung’s disease. (PMID:23836442)
• Here, we show that Wnt/planar cell polarity (PCP) autocrine signaling controls the emergence of cytonemes, and that cytonemes subsequently control paracrine Wnt/beta-catenin signal activation. Upon binding of the Wnt family member Wnt8a, the receptor tyrosine kinase Ror2 becomes activated. (PMID:30060804)
• Structural Basis of WLS/Evi-Mediated Wnt Transport and Secretion. (PMID:33357447)

Cross-species orthologs

10 orthologs

Organism	Symbol	Gene ID
danio_rerio	wnt8a	ENSDARG00000052910
danio_rerio	wnt8a	ENSDARG00000078507
mus_musculus	Wnt8a	ENSMUSG00000012282
rattus_norvegicus	Wnt8a	ENSRNOG00000020157
drosophila_melanogaster	Wnt2	FBGN0004360
drosophila_melanogaster	Wnt5	FBGN0010194
drosophila_melanogaster	Wnt10	FBGN0031903
caenorhabditis_elegans		WBGENE00000857
caenorhabditis_elegans		WBGENE00000858
caenorhabditis_elegans	lin-44	WBGENE00003029

Paralogs (18): WNT16 (ENSG00000002745), WNT8B (ENSG00000075290), WNT11 (ENSG00000085741), WNT2 (ENSG00000105989), WNT3 (ENSG00000108379), WNT5B (ENSG00000111186), WNT5A (ENSG00000114251), WNT6 (ENSG00000115596), WNT1 (ENSG00000125084), WNT2B (ENSG00000134245), WNT10A (ENSG00000135925), WNT9A (ENSG00000143816), WNT3A (ENSG00000154342), WNT7A (ENSG00000154764), WNT9B (ENSG00000158955), WNT4 (ENSG00000162552), WNT10B (ENSG00000169884), WNT7B (ENSG00000188064)

Protein

Protein identifiers

Protein Wnt-8a — Q9H1J5 (reviewed: Q9H1J5)

Alternative names: Protein Wnt-8d

All UniProt accessions (2): Q9H1J5, D6RF94

UniProt curated annotations — full annotation on UniProt →

Function. Ligand for members of the frizzled family of seven transmembrane receptors. Plays a role in embryonic patterning.

Subunit / interactions. Forms a soluble 1:1 complex with AFM; this prevents oligomerization and is required for prolonged biological activity. The complex with AFM may represent the physiological form in body fluids.

Subcellular location. Secreted. Extracellular space. Extracellular matrix.

Post-translational modifications. Palmitoleoylation is required for efficient binding to frizzled receptors. Depalmitoleoylation leads to Wnt signaling pathway inhibition. Proteolytic processing by TIKI1 and TIKI2 promotes oxidation and formation of large disulfide-bond oligomers, leading to inactivation of WNT8A.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Similarity. Belongs to the Wnt family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9H1J5-1	1	yes
Q9H1J5-2	2
Q9H1J5-3	3

RefSeq proteins (3): NP_001287867, NP_001287868, NP_490645 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005817	Wnt	Family
IPR013301	Wnt8	Family
IPR018161	Wnt_CS	Conserved_site
IPR034312	Protein_Wnt-8A/8C	Family
IPR043158	Wnt_C	Homologous_superfamily

Pfam: PF00110

UniProt features (40 total): disulfide bond 11, helix 8, strand 7, turn 6, glycosylation site 3, splice variant 2, signal peptide 1, chain 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
7KC4	ELECTRON MICROSCOPY	3.19

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H1J5-F1	83.78	0.63

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 186

Disulfide bonds (11): 182–189, 259–297, 275–290, 294–336, 312–327, 314–324, 319–320, 54–65, 104–112, 114–132, 180–194

Glycosylation sites (3): 103, 262, 281

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-201681	TCF dependent signaling in response to WNT
R-HSA-3238698	WNT ligand biogenesis and trafficking
R-HSA-373080	Class B/2 (Secretin family receptors)
R-HSA-4641262	Disassembly of the destruction complex and recruitment of AXIN to the membrane

MSigDB gene sets: 122 (showing top): GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_AXIS_SPECIFICATION, KEGG_HEDGEHOG_SIGNALING_PATHWAY, GOBP_NEUROGENESIS, GOBP_DORSAL_VENTRAL_PATTERN_FORMATION, GOBP_MESENCHYMAL_CELL_DIFFERENTIATION, GOBP_CANONICAL_WNT_SIGNALING_PATHWAY, GOBP_ANTERIOR_POSTERIOR_PATTERN_SPECIFICATION, KEGG_PATHWAYS_IN_CANCER, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_RESPONSE_TO_LIPID, GOMF_CYTOKINE_ACTIVITY, GOMF_G_PROTEIN_COUPLED_RECEPTOR_BINDING, GOBP_MESENCHYME_DEVELOPMENT, GOBP_ANTERIOR_POSTERIOR_AXIS_SPECIFICATION

GO Biological Process (11): anterior/posterior axis specification (GO:0009948), dorsal/ventral axis specification (GO:0009950), neural crest cell fate commitment (GO:0014034), neuron differentiation (GO:0030182), response to retinoic acid (GO:0032526), cell fate commitment (GO:0045165), positive regulation of transcription by RNA polymerase II (GO:0045944), canonical Wnt signaling pathway (GO:0060070), secondary palate development (GO:0062009), multicellular organism development (GO:0007275), Wnt signaling pathway (GO:0016055)

GO Molecular Function (4): frizzled binding (GO:0005109), cytokine activity (GO:0005125), receptor ligand activity (GO:0048018), signaling receptor binding (GO:0005102)

GO Cellular Component (3): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), extracellular matrix (GO:0031012)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Signaling by WNT	2
GPCR ligand binding	1
TCF dependent signaling in response to WNT	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
axis specification	2
cell differentiation	2
anterior/posterior pattern specification	1
dorsal/ventral pattern formation	1
neural crest formation	1
neural crest cell differentiation	1
stem cell fate commitment	1
generation of neurons	1
response to lipid	1
response to oxygen-containing compound	1
cellular developmental process	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
Wnt signaling pathway	1
roof of mouth development	1
multicellular organismal process	1
anatomical structure development	1
cell surface receptor signaling pathway	1
G protein-coupled receptor binding	1
receptor ligand activity	1
signaling receptor binding	1
signal transduction	1
signaling receptor activator activity	1
protein binding	1
cellular anatomical structure	1
external encapsulating structure	1

Protein interactions and networks

STRING

1046 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
WNT8A	LRP5	O75197	708
WNT8A	LRP6	O75581	702
WNT8A	FZD8	Q9H461	677
WNT8A	FZD4	Q9ULV1	676
WNT8A	RYK	P34925	663
WNT8A	FZD5	Q13467	656
WNT8A	FZD9	O00144	640
WNT8A	CTNNB1	P35222	579
WNT8A	DKK1	O94907	574
WNT8A	ROR2	Q01974	541
WNT8A	FNBP1L	Q5T0N5	508
WNT8A	FZD1	Q9UP38	507
WNT8A	AXIN2	Q9Y2T1	490
WNT8A	FZD2	Q14332	476
WNT8A	AXIN1	O15169	466
WNT8A	WNT10B	O00744	466

IntAct

5 interactions, top by confidence:

A	B	Type	Score
WNT8A	AFM	psi-mi:“MI:0915”(physical association)	0.400
WNT8A	WLS	psi-mi:“MI:0915”(physical association)	0.400
M		psi-mi:“MI:0914”(association)	0.350
WNT8A	STS	psi-mi:“MI:0914”(association)	0.350

BioGRID (6): WNT8A (Affinity Capture-MS), WNT8A (Affinity Capture-MS), STS (Affinity Capture-MS), TMPPE (Affinity Capture-MS), KCNJ8 (Affinity Capture-MS), WNT8A (Two-hybrid)

ESM2 similar proteins: A4D7S0, A8XEH1, O00755, O14904, O15978, O42280, P09544, P24383, P28026, P28047, P28107, P28111, P28130, P28144, P28465, P31291, P34888, P34889, P51028, P51029, P51030, P56706, Q07DW8, Q07DX7, Q07DY7, Q09YI4, Q09YJ6, Q10459, Q1KYK4, Q1KYK5, Q1KYK6, Q1KYK7, Q1KYK9, Q1KYL1, Q1KYL3, Q27886, Q2IBB0, Q2IBE2, Q2QL76, Q2QL96

Diamond homologs: A0M8S1, A0M8T2, A1X153, A4D7S0, A8XEH1, B2GUT4, O00755, O13267, O96014, P09544, P17553, P21552, P22725, P24383, P27467, P28047, P28105, P28106, P28108, P28111, P28116, P28127, P28135, P28138, P28143, P28465, P28466, P31283, P31284, P31285, P31286, P31287, P31288, P31289, P31290, P31292, P41221, P47793, P48615, P49337

SIGNOR signaling

6 interactions.

A	Effect	B	Mechanism
WNT8A	up-regulates	FZD3	binding
WNT8A	up-regulates	LRP5	binding
SOSTDC1	“down-regulates activity”	WNT8A
EXT1	“up-regulates activity”	WNT8A
FRZB	down-regulates	WNT8A	binding
WIF1	down-regulates	WNT8A	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

56 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	52
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

954 predictions. Top by Δscore:

Variant	Effect	Δscore
5:138084632:AAGTG:A	donor_gain	1.0000
5:138084634:GTG:G	donor_gain	1.0000
5:138084635:TG:T	donor_gain	1.0000
5:138084636:GG:G	donor_gain	1.0000
5:138084637:G:GG	donor_gain	1.0000
5:138084637:GT:G	donor_loss	1.0000
5:138084638:T:G	donor_loss	1.0000
5:138087801:CAAA:C	acceptor_loss	1.0000
5:138087802:A:AG	acceptor_gain	1.0000
5:138087803:A:G	acceptor_gain	1.0000
5:138087804:A:G	acceptor_gain	1.0000
5:138087804:AGC:A	acceptor_loss	1.0000
5:138087805:G:GC	acceptor_gain	1.0000
5:138087927:AACAG:A	donor_gain	1.0000
5:138087928:ACAG:A	donor_gain	1.0000
5:138087928:ACAGG:A	donor_loss	1.0000
5:138087929:CAG:C	donor_gain	1.0000
5:138087929:CAGGT:C	donor_loss	1.0000
5:138087930:AG:A	donor_gain	1.0000
5:138087931:GG:G	donor_gain	1.0000
5:138087931:GGTA:G	donor_loss	1.0000
5:138087932:G:GG	donor_gain	1.0000
5:138088921:A:AG	acceptor_gain	1.0000
5:138088922:T:G	acceptor_gain	1.0000
5:138088922:TATAG:T	acceptor_loss	1.0000
5:138088923:ATAG:A	acceptor_gain	1.0000
5:138088924:TA:T	acceptor_loss	1.0000
5:138088925:AG:A	acceptor_gain	1.0000
5:138088925:AGG:A	acceptor_loss	1.0000
5:138088925:AGGAG:A	acceptor_gain	1.0000

AlphaMissense

2455 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:138090964:T:G	F316C	0.999
5:138084584:G:C	W63C	0.998
5:138084584:G:T	W63C	0.998
5:138090963:T:C	F316L	0.998
5:138090965:C:A	F316L	0.998
5:138090965:C:G	F316L	0.998
5:138087832:G:C	A90P	0.997
5:138087844:G:C	A94P	0.997
5:138088946:G:C	W129C	0.997
5:138088946:G:T	W129C	0.997
5:138090971:G:C	W318C	0.997
5:138090971:G:T	W318C	0.997
5:138084582:T:A	W63R	0.996
5:138084582:T:C	W63R	0.996
5:138087874:T:A	C104S	0.996
5:138087875:G:C	C104S	0.996
5:138088974:G:T	G139W	0.996
5:138090561:T:A	C182S	0.996
5:138090562:G:C	C182S	0.996
5:138084555:T:A	C54S	0.995
5:138084556:G:C	C54S	0.995
5:138087876:T:G	C104W	0.995
5:138088940:G:C	W127C	0.995
5:138088940:G:T	W127C	0.995
5:138088953:T:A	C132S	0.995
5:138088954:G:C	C132S	0.995
5:138089051:C:A	N164K	0.995
5:138089051:C:G	N164K	0.995
5:138090597:T:A	C194S	0.995
5:138090598:G:C	C194S	0.995

dbSNP variants (sampled 300 via entrez): RS1000010025 (5:138088385 C>G), RS1000515504 (5:138083156 C>G), RS1000576408 (5:138075509 G>A), RS1000620912 (5:138089939 G>A), RS1000658499 (5:138076560 A>G), RS1000783102 (5:138081598 G>A), RS1001179637 (5:138082870 C>A), RS1001663492 (5:138075508 C>T), RS1001846707 (5:138089432 T>C), RS1002353008 (5:138082618 G>A), RS1002393000 (5:138081552 A>G), RS1002618682 (5:138079067 G>C), RS1002630018 (5:138078710 C>G,T), RS1002681526 (5:138092632 T>C), RS1003189305 (5:138085773 G>T)

Disease associations

OMIM: gene MIM:606360 | disease phenotypes: MIM:300633, MIM:135700

GenCC curated gene-disease

Mondo (2): hypospadias (MONDO:0005345), congenital fibrosis of extraocular muscles (MONDO:0007614)

Orphanet (2): Congenital fibrosis of extraocular muscles (Orphanet:45358), OBSOLETE: Familial hypospadias (Orphanet:440)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000047	Hypospadias

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001499_5	Atrial fibrillation	3.000000e-07
GCST004297_4	Atrial fibrillation	1.000000e-08
GCST004521_66	Autism spectrum disorder or schizophrenia	1.000000e-08
GCST005351_18	Carboplatin disposition in epthelial ovarian cancer	4.000000e-06
GCST006061_7	Atrial fibrillation	3.000000e-30
GCST006414_139	Atrial fibrillation	1.000000e-35

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D007021	Hypospadias	C12.050.351.875.466; C12.100.500.494.400; C12.200.294.494.400; C12.200.706.516; C12.800.516; C16.131.939.516
C580012	congenital fibrosis of the extraocular muscles (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

11 total (human), top 11 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
entinostat	increases expression, affects cotreatment	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, increases expression	1
Panobinostat	affects cotreatment, increases expression	1
Microplastics	decreases expression, increases abundance	1
Acetaminophen	increases expression	1
Arsenic	affects methylation	1
Carbamazepine	affects expression	1
Fluorouracil	decreases expression	1
Polystyrenes	decreases expression, increases abundance	1
Valproic Acid	increases expression	1

Clinical trials (associated diseases)

89 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02848157	PHASE4	COMPLETED	Effects of Dexmedetomidine as Adjunct to Pudendal Block for Pediatric Penile Surgery
NCT02861950	PHASE4	COMPLETED	Does Caudal Block Increase the Incidence of Urethrocutaneous Fistula Formation Following Hypospadias Repair in Infants?
NCT03902249	PHASE4	COMPLETED	Effect of Intravenous Dexamethasone With Pudendal Nerve Block on Postoperative Pain in Pediatric Hypospadias Repair
NCT05708989	PHASE4	WITHDRAWN	Caudal vs. Pudendal Block in Peds GU
NCT05837000	PHASE4	UNKNOWN	Dexmedetomidine, Ketamine and Magnesium Sulphate in Caudal Block for Hypospadias Repair
NCT05922605	PHASE4	UNKNOWN	Analgesic Effects of Caudal S-ketamine for Supplementation of Ropivacaine Caudal Analgesia in Children With Hypospadias
NCT07121764	PHASE4	COMPLETED	Postoperative Pain Relief in Children: Comparing Caudal Bupivacaine Alone Versus Bupivacaine With Dexmedetomidine for Infra-Umbilical Surgeries Under General Anesthesia
NCT07240649	PHASE4	NOT_YET_RECRUITING	Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
NCT01370798	PHASE3	COMPLETED	Local Oestrogen Versus Placebo as Preoperative Treatment in Patients With Severe Hypospadias: Effects on Post-operative Complications
NCT04423107	PHASE3	UNKNOWN	Assessment of Postop Hypospadias Pain
NCT04826484	PHASE3	TERMINATED	Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel
NCT07197203	PHASE3	NOT_YET_RECRUITING	Comparison of Caudal Block and Sacral Erector Spinae Plane Block With Dexmedetomidine in Pediatric Penile Hypospadias Repair
NCT05253456	PHASE2	COMPLETED	Modified Second Layer Repair for Distal Penile Hypospadias
NCT04479371	PHASE1	WITHDRAWN	Liposomal Bupivacaine vs Standard Penile Block for Hypospadias Repair
NCT02752308	PHASE2/PHASE3	COMPLETED	Effectiveness of Caudal Epidural Block on Intraoperative Blood Loss During Hypospadias Repair
NCT04876976	PHASE2/PHASE3	COMPLETED	Isoamyl 2-Cyanoacrylate in the Urethro-cutaneous Fistula Repair
NCT05093166	PHASE1/PHASE2	TERMINATED	Clinical Trial to Assess the Safety and Efficacy of Investigational Product in Patients Due to Hypospadias Treatment Failure
NCT04196400	EARLY_PHASE1	UNKNOWN	The Role of Local Long Acting Corticosteroid Injection in Hypospadias Surgery.
NCT01762007	Not specified	WITHDRAWN	The Change of the Detrusor Thickness After Hypospadias Repair - Comparison With the Normal Control Group
NCT01875640	Not specified	COMPLETED	Decision Support for Parents Receiving Information About Child’s Rare Disease
NCT02040389	Not specified	COMPLETED	Visual Guidelines and Tutoring in Pediatric Urological Surgery
NCT02096159	Not specified	ACTIVE_NOT_RECRUITING	Prophylactic Antibiotics or Placebo After Hypospadias Repair
NCT02103712	Not specified	COMPLETED	Long Term Outcome of Hypospadias Repair
NCT02162810	Not specified	TERMINATED	Effect of Steroids on Post-Operative Complications Following Proximal Hypospadias Repair
NCT02164682	Not specified	COMPLETED	The Effect of Caudal Block on the Postoperative Complications in Pediatric Patients After Hypospadias Repair
NCT02495090	Not specified	COMPLETED	Hypospadias and Exome: Identification of New Genes for Familial Hypospadias
NCT02497963	Not specified	UNKNOWN	Foreskin Graft Tubularized Incised Plate Urethroplasty vs Tubularized Incised Plate for Primary Hypospadias (FGTIP-TIP)
NCT02512887	Not specified	UNKNOWN	Caudal vs Local Anesthesia in Hypospadias
NCT02593903	Not specified	COMPLETED	Antibiotic Use Following Distal and Mid-shaft Hypospadias Repair
NCT02805491	Not specified	COMPLETED	Influence of Pesticide Exposure on the Occurrence of Hypospadias in Newborns in Picardie
NCT02851290	Not specified	COMPLETED	Effect of Caudal and Penile Block on Hypospadias Repair Complications
NCT03102554	Not specified	ENROLLING_BY_INVITATION	Genetics of Differences of Sex Development and Hypospadias
NCT03275519	Not specified	COMPLETED	Antibiotic Use in Distal Hypospadias Repair
NCT03575377	Not specified	COMPLETED	Opioid Use, Storage, and Disposal Among Pediatric Patients After Surgery
NCT03593720	Not specified	COMPLETED	Glans Size in Hypospadias Compared to Normal
NCT03677453	Not specified	COMPLETED	Interactive Perioperative Teaching Platform (IPTP)
NCT03685955	Not specified	WITHDRAWN	Efficacy of Amniotic Membranes in Complex Genitourinary Reconstruction
NCT03698721	Not specified	NOT_YET_RECRUITING	Urothelium Tissue Engineering Using Biopsies From Transurethral Resection of Prostate
NCT03838458	Not specified	COMPLETED	Molecular and Structural Comparison of Hypospadic and Normal Children Prepuces
NCT03911635	Not specified	UNKNOWN	Selective Criteria and a Modified Technique of Applying URAGPI Technique for More Proximal Degree of Hypospadias